Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a Two-Pill combo calm the Gut's inflammatory fire?

NCT ID NCT07767370

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This early-stage trial explores whether adding two experimental capsules, ND-12 and H-6, to standard mesalazine treatment can better control chronic inflammatory diarrhea in adults, including those with active ulcerative colitis. Participants will take the combination or a placebo for 14 days. The study measures changes in a stool marker of gut inflammation (fecal calprotectin) and tracks how many people achieve a meaningful clinical response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ND-12 and H-6 capsules combined with mesalazine
What this could lead to
If it works, this combination could offer a new way to reduce gut inflammation and improve symptoms for people with chronic inflammatory diarrhea.
What could go wrong
This is a very early, small trial, so results may not hold up in larger studies. The treatment could also cause side effects or fail to outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects aged 18-75 years (inclusive), of any gender. 2. Meet any one of the following conditions: 1) Previously diagnosed ulcerative colitis, currently in the active phase; 2) Diagnosis of chronic diarrhoea: stool frequency ≥3 times per day or markedly higher than the subject's usual baseline; disease duration \>4 weeks; recurrent diarrhoea with an interval of 2-4 weeks between episodes; loose stools (Bristol Stool Form Scale type 5, 6, or 7). 3\. Faecal calprotectin \>150 μg/g. 4.The subject or their legal representative provides informed consent by voluntarily signing the informed consent form, fully understands the study objectives, maintains effective communication with investigators, and is capable of understanding and complying with all requirements specified in this study protocol. Exclusion Criteria: Exclusion criteria related to chronic diarrhoea 1. Presence of any of the following symptoms: 1. Fever ≥37.5°C; 2. Moderate-to-severe dehydration requiring intravenous fluid replacement; 3. Recurrent vomiting. 2. Diarrhoea caused by enteric pathogens (e.g., Clostridioides difficile, Salmonella typhi, etc.). 3. Underlying diseases that may trigger diarrhoea, including hyperthyroidism, gastrointestinal autonomic nervous dysfunction, gastrointestinal malignancy, Crohn's disease, history of colectomy (appendectomy, haemorrhoid surgery and fistula-in-ano surgery excluded), history of small-bowel resection (\>20 cm of resected intestinal segment), etc. Drug-related exclusion criteria 4. Suspected drug-induced diarrhoea (e.g., long-term use of laxatives, antibiotics, chemotherapeutic agents, etc.) where discontinuation of the offending drug is not feasible. 5. History of allergy to any component of mesalazine capsules, ND-12 capsules or H-6 capsules. 6. Anticipated need for prohibited medications during the study (e.g. antibiotics, antidiarrhoeals, antiemetics, antispasmodics, etc.). 7. Use of any investigational drug within 30 days prior to enrolment into this study. Other gastrointestinal exclusion criteria 8. History of gastrectomy or vagotomy. 9. Known malabsorptive disorders include coeliac disease. 10. Known lactose intolerance. 11. Any suspected condition requiring abdominal surgery. Other exclusion criteria 12. Confirmed human immunodeficiency virus (HIV) positive status, known or suspected immunosuppression. 13. Known severe hepatic or renal insufficiency. 14. Past or current history of alcohol abuse and/or known substance abuse (cocaine, heroin, cannabis, etc.). 15. Any psychiatric condition impairing the subject's ability to understand the nature, scope and potential consequences of the study, and/or documented evidence of non-cooperation. 16. Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diarrhea chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.